David T. Curiel

39.2k citations

595 papers · 28.6k indexed · 5 hit papers · h-index 86

Genetics top 0.01%
- Virus-based gene therapy research 454
Oncology top 0.05%
- CAR-T cell therapy research 226
Biotechnology top 0.02%
- Cancer Research and Treatments 76
Molecular Biology top 0.1%
- Viral Infectious Diseases and Gene Expression in Insects 176
- RNA Interference and Gene Delivery 162
- CRISPR and Genetic Engineering 53
Immunology top 0.5%
- Immunotherapy and Immune Responses 59
Infectious Diseases
- Viral gastroenteritis research and epidemiology 48

Co-authors: Victor Krasnykh Igor P. Dmitriev Ramón Alemany Joanne T. Douglas Galina Mikheeva Ronald D. Alvarez Gene P. Siegal Minghui Wang
Cited by: Genetics Oncology Biotechnology
Journals: Proceedings of the National Academy of Sciences (6 papers)Nucleic Acids Research (1 paper)Journal of Biological Chemistry (5 papers)
Partner nations: United States France Netherlands

In The Last Decade

David T. Curiel

589 papers receiving 27.9k citations

Hit Papers

5 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2021 npj Vaccines
2017 Proceedings of the National Academy of Sciences
2007 Nature Reviews Genetics
2001 Nature Medicine
1998 Journal of Virology

Peers

Countries citing papers authored by David T. Curiel

Since Specialization

Citations

This map shows the geographic impact of David T. Curiel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Curiel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Curiel more than expected).

Fields of papers citing papers by David T. Curiel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Curiel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Curiel. The network helps show where David T. Curiel may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David T. Curiel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David T. Curiel Line = papers co-authored together David T. Curiel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Nonreciprocity in CHIKV and MAYV Vaccine-Elicited Protection Vaccines ·Whitney C. Weber,Takeshi F. Andoh,Craig N. Kreklywich,Zachary J. Streblow,Michael Denton,Magdalene M. Streblow,John M. Powers,Gauthami Sulgey,Samuel Medica,Igor P. Dmitriev,David T. Curiel,Nicole N. Haese,Daniel N. Streblow	2024	3
2	In vivo editing of the pan-endothelium by immunity evading simian adenoviral vector Biomedicine & Pharmacotherapy ·Réka Lőrincz,Aluet Borrego Alvarez,Christopher J. Walkey,Samir Andrade Mendonça,Zhi Hong Lu,Alexa Martinez,M. Cecilia Ljungberg,Jason D. Heaney,William R. Lagor,David T. Curiel	2022	7
3	Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma Clinical Cancer Research ·Michael I. Chastkofsky,Katarzyna C. Pituch,Hiroaki Katagi,Μαρκέλλα Ζαννίκου,Liliana Ilut,Ting Xiao,Yu Han,Adam M. Sonabend,David T. Curiel,Erin R. Bonner,Javad Nazarian,Craig Horbinski,C. David James,Amanda Saratsis,Rintaro Hashizume,Maciej S. Lesniak,Irina V. Balyasnikova	2020	52
4	COX2/mPGES1/PGE ₂ pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cellsbreakdown → Proceedings of the National Academy of Sciences ·Victor Prima,Lyudmila N. Kaliberova,Sergey A. Kaliberov,David T. Curiel,Sergei Kusmartsev	2017	374
5	A One Health overview, facilitating advances in comparative medicine and translational research Clinical and Translational Medicine ·Cheryl Stroud,Igor P. Dmitriev,Elena A. Kashentseva,Jeffrey N. Bryan,David T. Curiel,Hans Rindt,Carol R. Reinero,Carolyn J. Henry,Philip J. Bergman,Nicola J. Mason,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	2016	17
6	A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models Clinical Cancer Research ·Helga L. Weber,Manuel Gidekel,Santiago Werbajh,Edgardo Salvatierra,Cecilia Rotondaro,Leonardo Sganga,Gabriela Acosta Haab,David T. Curiel,Eduardo G. Cafferata,Osvaldo L. Podhajcer	2015	9
7	A Phase I Clinical Trial of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Patients with Recurrent Gynecologic Cancer Clinical Cancer Research ·Kenneth H. Kim,Igor P. Dmitriev,Janis P. O’Malley,Minghui Wang,Souheil Saddekni,Zhiying You,Meredith A. Preuss,Raymond D. Harris,Rosemarie Aurigemma,Gene P. Siegal,Kurt R. Zinn,David T. Curiel,Ronald D. Alvarez	2012	49
8	Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine Cancer Research ·Basav N. Hangalapura,Dinja Oosterhoff,Jan de Groot,Louis Boon,Thomas Tüting,Alfons J. van den Eertwegh,Winald R. Gerritsen,Victor W. van Beusechem,Alexander Pereboev,David T. Curiel,Rik J. Scheper,Tanja D. de Gruijl	2011	26
9	Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda -7/IL-24–mediated toxicity Proceedings of the National Academy of Sciences ·Rupesh Dash,Belal Azab,Bridget A. Quinn,Xue‐Ning Shen,Xiangyang Wang,Swadesh K. Das,Mohamed Rahmani,Jun Wei,Michael Hedvat,Paul Dent,Igor P. Dmitriev,David T. Curiel,Steven Grant,Bainan Wu,John L. Stebbins,Maurizio Pellecchia,John C. Reed,Devanand Sarkar,Paul B. Fisher	2011	101
10	Mechanism of Autophagy to Apoptosis Switch Triggered in Prostate Cancer Cells by Antitumor Cytokine Melanoma Differentiation-Associated Gene 7/Interleukin-24 Cancer Research ·Sujit K. Bhutia,Rupesh Dash,Swadesh K. Das,Belal Azab,Zhao-zhong Su,Seok‐Geun Lee,Steven Grant,Adly Yacoub,Paul Dent,David T. Curiel,Devanand Sarkar,Paul B. Fisher	2010	102
11	PERK–Dependent Regulation of Ceramide Synthase 6 and Thioredoxin Play a Key Role in mda -7/IL-24–Induced Killing of Primary Human Glioblastoma Multiforme Cells Cancer Research ·Adly Yacoub,Hossein A. Hamed,Jeremy C. Allegood,Clint Mitchell,Sarah Spiegel,Maciej S. Lesniak,Besim Öğretmen,Rupesh Dash,Devanand Sarkar,William C. Broaddus,Steven Grant,David T. Curiel,Paul B. Fisher,Paul Dent	2010	89
12	Mechanism by Which Mcl-1 Regulates Cancer-Specific Apoptosis Triggered by mda-7/IL-24, an IL-10–Related Cytokine Cancer Research ·Rupesh Dash,Joanna E. Richards,Zhao-zhong Su,Sujit K. Bhutia,Belal Azab,Mohamed Rahmani,Girija Dasmahapatra,Adly Yacoub,Paul Dent,Igor P. Dmitriev,David T. Curiel,Steven Grant,Maurizio Pellecchia,John C. Reed,Devanand Sarkar,Paul B. Fisher	2010	65
13	Combined Transductional Untargeting/Retargeting and Transcriptional Restriction Enhances Adenovirus Gene Targeting and Therapy for Hepatic Colorectal Cancer Tumors Cancer Research ·Hua‐Jung Li,Maaike Everts,Masato Yamamoto,David T. Curiel,Harvey R. Herschman	2009	22
14	MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism Molecular Cancer Therapeutics ·Margaret A. Park,Teneille Walker,Aditi Pandya Martin,Jeremy C. Allegood,Nicollaq Vozhilla,Luni Emdad,Devanand Sarkar,Mohamed Rahmani,Martin Graf,Adly Yacoub,Constantinos Koumenis,Sarah Spiegel,David T. Curiel,Christina Voelkel‐Johnson,Steven Grant,Paul B. Fisher,Paul Dent	2009	40
15	Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation Clinical Cancer Research ·Guo Zhang,Margaret A. Park,Clint Mitchell,Hossein A. Hamed,Mohamed Rahmani,Aditi Pandya Martin,David T. Curiel,Adly Yacoub,Martin R. Graf,Ray Lee,John D. Roberts,Paul B. Fisher,Steven Grant,Paul Dent	2008	101
16	Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95 Molecular Cancer Therapeutics ·Margaret A. Park,Guo Zhang,Clint Mitchell,Mohamed Rahmani,Hossein A. Hamed,Michael P. Hagan,Adly Yacoub,David T. Curiel,Paul B. Fisher,Steven Grant,Paul Dent	2008	41
17	Ionizing radiation enhances adenoviral vector expressing mda‐7/IL‐24‐mediated apoptosis in human ovarian cancer Journal of Cellular Physiology ·Luni Emdad,Devanand Sarkar,Irina V. Lebedeva,Zao‐zhong Su,Pankaj Gupta,Parameshwar J. Mahasreshti,Paul Dent,David T. Curiel,Paul B. Fisher	2006	33
18	Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures Molecular Cancer Therapeutics ·N. Sanjib Banerjee,Ángel A. Rivera,Minghui Wang,Louise T. Chow,Thomas R. Broker,David T. Curiel,Dirk M. Nettelbeck	2004	46
19	Tumor immunotherapy: inching toward the finish line Journal of Clinical Investigation ·Tyler J. Curiel,David T. Curiel	2002	11
20	Tumor immunotherapy: inching toward the finish line Journal of Clinical Investigation ·Tyler J. Curiel,David T. Curiel	2002	1

About David T. Curiel

David T. Curiel is a scholar working on Genetics, Oncology and Biotechnology, having authored 595 papers that have together received 28.6k indexed citations. Recurring topics across this work include Virus-based gene therapy research (454 papers), CAR-T cell therapy research (226 papers), Viral Infectious Diseases and Gene Expression in Insects (176 papers), RNA Interference and Gene Delivery (162 papers), Cancer Research and Treatments (76 papers), Immunotherapy and Immune Responses (59 papers), CRISPR and Genetic Engineering (53 papers) and Viral gastroenteritis research and epidemiology (48 papers). The work is most often cited by research in Genetics (17.4k citations), Oncology (11.0k citations) and Biotechnology (3.2k citations). David T. Curiel has collaborated with scholars based in United States, France and Netherlands. Frequent co-authors include Victor Krasnykh, Igor P. Dmitriev, Ramón Alemany, Joanne T. Douglas, Galina Mikheeva, Ronald D. Alvarez, Gene P. Siegal, Minghui Wang, Elena A. Kashentseva and Masato Yamamoto. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact